LL-37

Cathelicidin antimicrobial peptide for immune defence research.

Half-life~30 minutes plasma
Dose range100 to 500 mcg/day subcutaneous · 4 to 8 week cycle
Reconstituted stability28 days, 2–8 °C
VerificationCOA included

Mechanism

How it works.

Direct antimicrobial action via membrane disruption. Modulates innate immune signalling and chemotaxis.

Research

What the research shows.

Strong antimicrobial-research literature in vitro and animal models. Wound-healing and immune-defence applications are the most-studied research-context uses.

LL-37 is a synthetic version of the human cathelicidin antimicrobial peptide. The compound has broad-spectrum antimicrobial activity and modulates innate immune signalling.

Research-context use focuses on antimicrobial defence, wound-healing support, and immune regulation. The peptide can be pro-inflammatory at higher concentrations, which is why dose patterns lean conservative.

Contraindications

When not to use.

Active autoimmune disease. Pregnancy. Pediatric use without clinical oversight.

Optimal pairings

Stacks well with.

Pentadecapeptide · Synthetic gastric peptide BPC-157 View → Tripeptide α-MSH fragment (Lys-Pro-Val) KPV View →

Tool Calculate dose → Reconstitution math + syringe units Tool Build a stack → Get a curated protocol with this compound Shop Buy LL-37 → COA included · cold-chain dispatched

Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.